The reiteration of a Buy rating and maintenance of a $17 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong belief in the future performance of Tango Therapeutics. This endorsement is likely to instill confidence in investors, potentially leading to a positive short-term impact on the stock's price.